Therapeutic Effects of *Cyathula officinalis* Kuan and Its Active Fraction on Acute Blood Stasis Rat Model and Identification Constituents by HPLC-QTOF/MS/MS

Yanmei Cao, Cuicui Gu, Fangli Zhao, Yuanlin Tang, Xiaobing Cui, Le Shi, Li Xu, Lian Yin

Department of Chinese Materia Medica, College of Pharmacy, Nanjing University of Chinese Medicine, 210023 Nanjing, China

Submitted: 12-12-2016  Revised: 04-01-2017  Published: 13-11-2017

**ABSTRACT**

**Background:** *Cyathula officinalis* Kuan is widely used in the clinics for the treatment of blood stasis in China. **Objective:** To evaluate the improving blood rheology and anti-inflammatory properties of *C. officinalis* Kuan extract (CO) and its active fraction (ACO) on acute blood stasis model Wistar rats and characterize the correlative constituents. **Materials and Methods:** CO at 0.26, 0.53, and 1.04 g/kg and ACO at 0.38, 0.75, and 1.5 g/kg were administered to acute blood stasis model Wistar rats for 3 days. Whole blood viscosity, plasma viscosity, and the levels of interleukin-6 (IL-6), nitric oxide (NO), tumor necrosis factor alpha (TNF-α), and cyclooxygenase-2 (COX-2) in the plasma were measured. HPLC-QTOF/MS/MS method was used to identify the major constituents of ACO; the properties of two representative components (cyasterone and chikusetsusaponin IV) from ACO on thrombin-induced human umbilical vein endothelial cells damage model were also assessed by the levels of thromboxane A2 (TXA2), endothelin (ET), malondialdehyde (MDA), COX-2, endothelial nitric oxide synthase (eNOS), and superoxide dismutase (SOD). **Results:** CO and ACO significantly reduced whole blood viscosity, plasma viscosity, and levels of IL-6, NO, TNF-α, and COX-2 in vivo. Forty compounds were identified from ACO, mainly as phytoecdysteroids and saponins. Cyasterone and chikusetsusaponin IV could significantly inhibit levels of TXA2, ET, MDA, and COX-2 and promote the activities of eNOS and SOD in vitro. **Conclusion:** CO and ACO possessed significant improving blood rheology and anti-inflammatory effects on acute blood stasis model rats and the representative components Cyasterone and chikusetsusaponin IV showed significant anti-inflammatory, antioxidant, and anticoagulant effects in vitro. **Key words:** Acute blood stasis model rats, anti-inflammatory, *Cyathula officinalis* Kuan, HPLC-QTOF/MS/MS, improving blood rheology

**SUMMARY**

- *Cyathula officinalis* Kuan is widely used in the clinic for the treatment of blood stasis in China
- The *C. officinalis* Kuan extract and the active fraction of *C. officinalis* Kuan (ACO) possessed significant improving blood rheology and anti-inflammatory effects on acute blood stasis model rats
- Forty compounds were identified from ACO, mainly as phytoecdysteroids and saponins

**INTRODUCTION**

*Cyathula officinalis* Kuan (“Chuan Niu Xi” in Chinese) deriving from the root of *C. officinalis* (Amaranthaceae family), which is a commonly used medicinal plant, plays an important role in the clinical treatment of Traditional Chinese Medicine (TCM) with functions of strengthening bones and muscles and activating blood and removing blood stasis. [1] It is a safe and effective herb widely used for the treatment of lower extremity joint pain, joint flexion, and extension negative, inducing urination and relieving stranguria with a medicinal history of more than 1000 years. It can be mainly used to activate blood and remove blood stasis in clinical application, such as treatment of cardiovascular and cerebrovascular diseases, arthritis, and dysmenorrhea. *C. officinalis* Kuan has been listed in Chinese Pharmacopoeia as a blood-activating herb and is a health tonic. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Cite this article as: Cao Y, Gu C, Zhao F, Tang Y, Cui X, Shi L, et al. Therapeutic effects of *Cyathula officinalis* Kuan and its active fraction on acute blood stasis rat model and identification constituents by HPLC-QTOF/MS/MS. Phcog Mag 2017;13:693-701.
The aqueous extract of *C. officinalis* Kuan (CO) has been reported to exhibit anti-inflammatory activity through inhibiting the mice auricle tumefaction degree induced by xylol and rats' feet swelling caused by egg white. Various components, such as phytoceramides, saponins, flavones, and polysaccharides, have been identified from *C. officinalis* Kuan. Modern pharmacological studies are mostly focused on the activities of polysaccharides from *C. officinalis* Kuan. For example, the polysaccharides of *C. officinalis* Kuan have been reported to possess immune enhancement activity by upregulating humoral and cellular immune responses. Besides, a water-soluble polysaccharide has been reported to have significant antioxidative activity, and a fructan CoPS3 could effectively inhibit the growth of Lewis pulmonary carcinoma implanted in mice.

At present, there is no systematic research conducted on *C. officinalis* Kuan, especially the therapeutic effects on blood stasis model and correlative components. The active fraction of *C. officinalis* Kuan (ACO) responsible for anti-inflammatory and protective effects on endothelial cells (human umbilical vein endothelial cells [HUVECs]) injury has been investigated previously.

In this study, the effects of CO and ACO on improving blood rheology and anti-inflammatory properties were examined in acute blood stasis model rats, and the major constituents of ACO were identified by HPLC-QTOF/MS/MS method. Besides, the effects of two representative components (cyasterone and chikusetsusaponin IV) from ACO on thrombin-induced HUVECs damage model were also assessed by levels of thromboxane A2 (TXA2), endothelin (ET), malondialdehyde (MDA), cyclooxygenase-2 (COX-2), endothelial nitric oxide synthase (eNOS), and superoxide dismutase (SOD).

**MATERIALS AND METHODS**

**Chemicals and reagents**

Chloral hydrate was purchased from Sinopharm Chemical Reagent Beijing Co., Ltd; adrenaline hydrochloride injection was purchased from Shanghai Harvest Pharmaceutical Co., Ltd.; cyasterone (C_{29}H_{36}O_{18}, MW 520.65) and chikusetsusaponin IV (C_{44}H_{68}O_{29}, MW 927.08) with a purity of 98% as determined by HPLC were purchased from SenBeijia Biological Technology Co., Ltd. (Nanjing, China). Ethanol, petroleum ether, dichloromethane, and n-butanol (chemical pure), methanol (HPLC grade) were supplied by Tedia Company Inc. (Fairfield, USA). HPLC-grade formic acid was purchased from Merck Corporation (Darmstadt, Germany). Enzyme-linked immunosorbent assay (ELISA) kits for interleukin-6 (IL-6), nitric oxide (NO), tumor necrosis factor alpha (TNF-α), COX-2, TXA2, ET, MDA, eNOS, and SOD were obtained from Roche Diagnostics (Mannheim, Germany). HUVECs and thrombin were purchased from Yi Fei Xue Biotechnology (Nanjing, China). Dulbecco’s modified Eagle medium (DMEM) and fetal bovine serum were obtained from Invitrogen (Life Technologies Corporation, Carlsbad, CA, USA). All other reagents were of analytical grade, and distilled water was used to extract and prepare the samples.

**Plant material**

*C. officinalis* Kuan was obtained in Sichuan Province, China, in December 2015 (No. 151201). It was identified and authenticated by Prof. Wu-De Kang of the School of Pharmacy of the Nanjing University of Chinese Medicine. A voucher specimen was deposited at the Nanjing University of Chinese Medicine, Nanjing 210023, PR, China.

**Extraction procedures**

The dried *C. officinalis* Kuan (1.6 kg) was turned into powder form and refluxed with the 85% ethanol for 10 times (3 times × 1.5 h). The extracts were concentrated under vacuum and dried, obtaining CO (79.2 g, with respect to 1.6 kg of the plant material). Then, CO (47 g, with respect to 950 g of the plant material) was resuspended in distilled water and submitted to sequential extraction with petroleum ether, dichloromethane, and n-butanol (5 times), obtaining n-butanol fraction. Then, n-butanol extract was concentrated under vacuum and dried, obtaining the ACO (33.5 g, with respect to 950 g of the plant material). The samples were stored at −4°C until used.

**Animals**

Male Wistar rats (200 ± 30 g) were provided by the Shanghai Jiesijie Experimental Animal Center with animal license: Certificate No. SCXK (Hu) 2013-0006. Animals were housed in a standard breeding room (25°C, relative humidity, 12 h dark-light cycle). All animals were acclimated in the laboratory for at least 7 days before the experiment. The animals were given chow and water ad libitum but fasted overnight before the operation. The experiment was approved by the Animal Ethics Committee of Nanjing University of Chinese Medicine and was conducted in accordance with the international guidelines for laboratory animal use and care published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996).

**Experimental model and drug administration**

Dosage of *C. officinalis* Kuan was determined based on the conversions from clinical adult dosage. Thus, the oral dosage in a rat of *C. officinalis* Kuan may be designed to be 5.3 g/kg (crude herbal dose). In the present study, the yields of CO and ACO were 4.95% and 3.53%, respectively. Meanwhile, the oral dosages of CO in the previous studies were taken into consideration in our present study. Therefore, we used three doses of CO at 0.26, 0.53, and 1.04 g/kg (equivalent to crude herbal doses 5.3, 10.8, and 21.3 g/kg, respectively) and ACO at 0.38, 0.75, and 1.5 g/kg (equivalent to crude herbal doses 10.8, 21.3, and 42.5 g/kg, respectively) in this study.

Seventy-two male Wistar rats approximately 7–8 weeks of age were randomly divided into nine groups (*n* = 8), including blank group, model group, aspirin group (0.1 g/kg), CO (0.26 g/kg), CO (0.53 g/kg), CO (1.04 g/kg), and ACO (0.38 g/kg), ACO (0.75 g/kg), ACO (1.5 g/kg) groups. All drug treatments were administered, respectively, by gavage for 3 days. Rats of blank group and model group were only orally administered normal saline. The day before taking blood, rats except the blank group were hypodermically injected with adrenaline hydrochloride (0.8 mL/kg) twice at an interval of 4 h. Two hours after the first injection of adrenaline hydrochloride, the rats were kept in ice-cold water (0–2°C) to swim for 5 min.

**Measurement of whole blood viscosity and plasma viscosity**

All animals were anesthetized with 10% chloral hydrate before surgery. Blood (3 mL) was immediately collected in heparinized tubes from the abdominal aorta. Blood samples (1 mL) were used for measuring the whole blood viscosity. Plasma samples were prepared by centrifuging at 3000 rpm for 15 min. Whole blood viscosity and plasma viscosity were measured as soon as possible by a LG-R-80 B automated viscometer.

**Measurement of plasma interleukin-6, nitric oxide, tumor necrosis factor-α, and cyclooxygenase-2 values**

Plasma samples were prepared by centrifuging at 3000 rpm for 15 min and the levels of IL-6, NO, TNF-α, and COX-2 were measured by ELISA kits (R and D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions. Briefly, ELISA plates were coated with specific IL-6, NO, TNF-α, or COX-2 antibody. Diluted plasma samples were
added into the wells in duplicate, followed by adding IL-6, NO, TNF-α, or COX-2 to wells, and incubated for 1 h at 37°C. After washing, hors eradish peroxidase-labeled IL-6, NO, TNF-α, or COX-2 monoclonal antibody was pipetted into the wells, and the plates were incubated for 1 h at 37°C. After washing completely, 3,3,5,5-tetramethylbenzidine substrate solution was added to the wells. Color development was stopped with sulfuric acid solution, and the intensity of the color was measured at 450 nm by an ELISA plate reader. Concentrations of the samples were determined by comparison with standard curves generated with purified isotypes.

The analysis of components of active fraction of *Cyathula officinalis* Kuan with HPLC-QTOF/MS/MS

Ten milligrams of ACO was dissolved in 1 mL methanol (HPLC grade) and filtered through a 0.45 μm filter to the analysis. HPLC-QTOF/MS/MS analysis was performed on an LC-20a Shimadzu HPLC system coupled to the orthogonal AB SCIEX Triple TOFTM 5600 mass spectrometry equipped with an electrospray ionization source (ESI). The chromatographic separation was achieved with a Thermo C18 ODS HYPERSIL column (150 mm × 4.6 mm, 5 μm) at 30°C. A mixture of solvent A (0.5% formic acid; v/v) and solvent B (methanol) was used as the mobile phase at a flow rate of 1 mL/min. The gradient elution program was as follows: 0–5 min, 5%–5% B; 5–20 min, 5%–40% B; 20–40 min, 40%–50% B; 40–50 min, 50%–75% B; 50–65 min, 75%–90% B; 65–75 min, 90%–100% B. The injection volume was 2 μL. ESI-MS spectra were operated in positive and negative ion modes, collecting full-scan MS data from 50 to 1500 m/z. The conditions of MS analysis were used as follows: capillary voltage, 2800 V; source temperature, 100°C; cone voltage, 20 V; collision energy, 35 V; spray voltage, 20 V; nebulizer, 55 psi; aux gas pressure, 60 psi; curtain gas, 40 psi; IS20V; gas flow 450 (L/HR); desolvation temperature 250°C; detector, time of flight mass spectrometer.

**Cell culture**

HUVECs were cultured in DMEM containing 10% fetal bovine serum and 1% penicillin/streptomycin solution at 37°C in a humidified incubator with 5% CO₂. The medium was changed every 48 h until cells reached 80%–90% confluency. After confluence, HUVECs were digested with 0.25% trypsin. Cells at passage 3–6 were used for the experiment.

**Enzyme-linked immunosorbsent assay**

Cells (2 × 10⁴ cells/well) were seeded in wells of 24-well plates, pretreated with aspirin (100 μM), cyasterone, or chikusetsusaponin IV (50, 100, and 200 μM) for 24 h, and then stimulated with thrombin (15 U/mL) for another 24 h. The levels of TXA2, ET, COX-2, MDA, eNOS, and SOD were measured in the supernatant using commercial ELISA kits.

**Statistical analysis**

All data were represented as mean ± standard deviation. Statistical analysis of data was performed with GraphPad Prism 5.0 software (GraphPad software, Inc., CA, USA) and was calculated using one-way analysis of variance (ANOVA). Values of *P* < 0.05 were considered statistical significance.

**RESULTS**

**Improving blood rheology effects of *Cyathula officinalis* Kuan extract and active fraction of *Cyathula officinalis* Kuan on acute blood stasis model rats**

As shown in Figure 1a and b, the values of whole blood viscosity under different shear rates and plasma viscosity of model group were obviously increased (*P* < 0.001) compared with the blank group, indicating that the model was constructed successfully. Compared with the model group, whole blood viscosity and plasma viscosity were significantly decreased to various degrees (*P* < 0.05 or *P* < 0.01 or *P* < 0.001) after the treatment with aspirin or CO (0.26, 0.53, 1.04 g/kg) or ACO (0.38, 0.75, 1.5 g/kg). Especially, at the same crude herbal dose, the improving blood rheology effects of ACO (0.75 g/kg, 0.38 g/kg) were same to CO (1.04 g/kg, 0.53 g/kg), respectively. Moreover, the effects of CO (1.04 g/kg) and ACO (0.75 g/kg, 1.5 g/kg) on improving blood rheology were same to aspirin group. The reduction of whole blood viscosity and plasma viscosity suggested that CO and ACO possessed a significant therapeutic effect on acute blood stasis model rats.

**Effects of *Cyathula officinalis* Kuan extract and active fraction of *Cyathula officinalis* Kuan on the plasma levels of interleukin-6, tumor necrosis factor-α, nitric oxide, and cyclooxygenase-2 of acute blood stasis model rats**

As shown in Figure 2a-d, the levels of IL-6, TNF-α, NO, and COX-2 in the model group were significantly higher than those in the blank group (*P* < 0.001). Compared with the model group, the levels of IL-6, TNF-α, NO, and COX-2 were significantly reduced (*P* < 0.001) in the aspirin group. As shown in Figure 2a and c, the levels of IL-6 and NO were significantly decreased in CO (0.26 g/kg, < 0.05, P < 0.05, 0.53, 1.04 g/kg, < 0.001) and

---

**Figure 1:** Whole blood viscosity at different shear rates (a) and plasma viscosity (b) on acute blood stasis model rats of aspirin group, the CO (0.26, 0.53, 1.04 g/kg) and ACO (0.38, 0.75, 1.5 g/kg) dose groups assay at 30 min after the last oral administration. Data are expressed as mean ± standard deviation (*n* = 8). ***P* < 0.001 as compared with the blank group. *P* < 0.05, **P < 0.01, ***P < 0.001 as compared with the model group. CO (1.04 g/kg) and ACO (0.75 g/kg) have a same crude herbal dose (21.3 g/kg); CO (0.53 g/kg) and ACO (0.38 g/kg) have a same crude herbal dose (10.8 g/kg). CO: *Cyathula officinalis* Kuan extract, ACO: Active fraction of *Cyathula officinalis* Kuan.
ACO (P < 0.001) groups compared with the model group. As shown in Figure 2b and d, the levels of TNF-α and COX-2 were significantly lower (P < 0.001) than those in the model group after treatment with CO (0.26, 0.53, 1.04 g/kg) and ACO (0.38, 0.75, 1.5 g/kg). Especially, at the same crude herbal dose, the inhibition of IL-6, TNF-α, NO, and COX-2 of ACO (0.75 g/kg, 0.38 g/kg) was same to CO (1.04 g/kg, 0.53 g/kg) groups, respectively. Moreover, the anti-inflammatory effects on the inhibition of IL-6, TNF-α, NO, and COX-2 in CO (1.04 g/kg) and ACO (0.75 g/kg) groups were same to aspirin group. What is noteworthy is that the levels of TNF-α and COX-2 in ACO (1.5 g/kg) group have significant differences (P < 0.01) compared with aspirin group.

**HPLC-QTOF/MS/MS analysis**

To accurately identify the components of ACO, HPLC-QTOF/MS/MS spectra in positive and negative ion modes were acquired. The total ion chromatogram in negative ion mode, which provided more MS spectra, and the MS/MS fragmentation data with relevant references. Compounds 1 and 30 were unambiguously identified as corysterol and chikusetsusaponin IV, respectively. Compounds 2, 4, 6, 9–12, 15–18, 20, 22–25, 27–29, 32–34, 36, 38–40 were tentatively identified based on a comparison of their MS and MS/MS fragmentation data with relevant references.

A comparison of the retention time with the reference standards and MS data from the literature, compounds 14 and 30 were unambiguously identified as corysterol and chikusetsusaponin IV, respectively. Compounds 2, 4, 6, 9–12, 15–18, 20, 22–25, 27–29, 32–34, 36, 38–40 were tentatively identified based on a comparison of their MS and MS/MS fragmentation data with relevant references.

**Figure 3:** Total ion current chromatogram of the active fraction of Cyathula officinalis Kuan
Figure 4: Structures of the components identified from the active fraction of Cyathula officinalis Kuan.

spectra[26] and m/z 301.319 and 475 in the MS spectra. Compound 26 was inferred as 28-O-β-D-glucuronopyranosyl-(1 → 4)-β-D-glucopyranosyl hederagenin by its ions at m/z 809[M-H] in the MS spectra[22] and m/z 647[M-H-Glc]⁻, 471[M-H-Glc-GluA]⁻ in the MS² spectra. Compound 31 was inferred as 3-O-[β-D-glucopyranosyl-(1 → 2)-α-L-rhamnopyranosyl-(1 → 3)-β-D-glucuronopyranosyl]-28-O-β-D-glucopyranosyl oleanolic acid by its ions at m/z 1101[M-H] in the MS spectra[22] and m/z 955[M-H-Rha]⁻, 939[M-H-Glc]⁻, 777[M-H-2Glc]⁻, 715[M-H-2Glc-H2O-CO2]⁻, 455[M-H-2Glc-Rha-GluA]⁻ in the MS² spectra. Compound 35 was inferred as chikusetsusaponin IVa methyl ester by its ions at m/z 807[M-H]⁻ in the MS spectra[22] and m/z 645[M-H-Glc]⁻, 455 in the MS² spectra. Compound 37 was inferred as 3-O-[α-L-rhamnopyranosyl-(1 → 3)-β-D-glucuronopyranosyl]-28-O-β-D-glucopyranosyl oleanolic acid by its ions at m/z 939[M-H]⁻ in the MS spectra[22] and m/z 793[M-H-Rha]⁻, 757[M-H-Rha-2H2O]⁻, 595[M-H-Rha-2H2O-Glc]⁻, 455 in the MS² spectra.

Effects of cyasterone and chikusetsusaponin IV on thrombin-induced human umbilical vein endothelial cells injury model

To determine the effects of cyasterone and chikusetsusaponin IV on thrombin-induced HUVECs injury model, the levels of TXA2, ET, COX-2, eNOS, and SOD in the supernatant were measured. Compared with blank group, when HUVECs were stimulated with thrombin (15 U/mL), the productions of MDA, COX-2, TXA2, ET were greatly increased (P < 0.001) and of SOD, eNOS were markedly decreased (P < 0.001). Cyasterone and chikusetsusaponin IV could effectively inhibit thrombin-stimulated TXA2, ET, COX-2, and MDA production and raise SOD and eNOS levels compared with the model group [Figure 5a-f]. Especially, the effect of chikusetsusaponin IV (200 μM) on inhibiting the levels of MDA, TXA2, ET and promoting the activity of SOD as well as cyasterone (100 μM) on inhibiting the levels of COX-2, ET and promoting the activity of SOD was better than aspirin group (100 μM). Taken together, the results profoundly suggested that cyasterone and chikusetsusaponin IV had significant protective effects against thrombin-induced HUVECs injury model.

DISCUSSION

Inflammation can damage the lining of the arteries and affect the viscosity of the blood, which is the major culprit to blood stasis. [23] Moreover, normal blood flow is essential for conveying oxygen and nutrients to cells and is also critical for removing metabolic wastes and reactive oxygen species (ROS). Consequently, blood stasis promotes an oxidative state where ROS accumulate. Oxidative stress and inflammation also promote blood flow abnormalities, causing a vicious pathophysiologic cycle.[24] As a result, regulating inflammation and oxidative stress is the important therapeutic approach for blood stasis.[25]

As we all know, C. officinalis Kuan is an effective blood-activating herb in clinical application in China with more than 1000 years of medicinal history. However, there is little information available on blood-activating effect and correlative ingredients of C. officinalis Kuan. Acute blood stasis rat model induced by ice water bath and subcutaneous injection of adrenaline hydrochloride is a common animal model in vivo studies.[22] Thus, this study systemically evaluated the improving blood rheology and anti-inflammatory properties of CO and ACO on acute blood stasis model rats by the assessment of whole blood viscosity, plasma viscosity, and levels of IL-6, TNF-α, NO, and COX-2. Endothelial dysfunction plays a pivotal role in the development of blood stasis,[27] and thrombin-induced HUVECs damage model is the most frequently used model to evaluate the protective effects of drugs in vitro. Hence, the effects of cyasterone and chikusetsusaponin IV on thrombin-induced HUVECs damage model were assessed by levels of TXA2, ET, MDA, COX-2, eNOS, and SOD.

IL-6 is an important marker for blood inflammation and the elevated level of IL-6 is associated with increased risk of blood stasis.[28] Besides, TNF-α, as a critical initiation factor and inflammatory peptide neurotransmitter released by macrophage, can cause fever, inflammation, and the production of a series of cytokines. Endothelial cell is an important target cell of TNF-α, and endothelial cell injury has important significance in the pathogenesis of blood stasis.[29] NO, as an important endothelium-derived substance, can relax blood vessel walls and improve blood circulation throughout the body. However, NO as a free radical is a vital mediator of both physiological and pathological reactions. [31] In addition, COX-2 is seldom expressed in most cells under...
| Name                                                                 | Retention time (min) | MS/MS/MS | MW    | MF    | Reference |
|----------------------------------------------------------------------|----------------------|-----------|-------|-------|-----------|
| Succinic acid                                                        | 4.65                 | 117[M–H] | 7399  | C₇H₆O₂ | [8]       |
| Arbutin                                                              | 13.9                 | 271[M–H] | 91,109| C₁₅H₁₆O₉ | [9]       |
| Phenyl-β-D-glucopyranoside                                           | 14.05                | 301[M+HCOO] | 93,161,255 | C₆H₁₇O₄ | [8]       |
| Geniposide                                                           | 18.39                | 387[M–H] | 163,207,225 | C₁₇H₁₈O₉ | [10]      |
| Lyoniresinol-3a-O-β-D-glucopyranoside                                | 20.63                | 581[M–H] | 233,371,419 | C₁₅H₁₇O₇ | [11]      |
| Vitexin                                                              | 22.5                 | 431[M–H] | 283,311,341 | C₁₅H₁₇O₉ | [12]      |
| N-trans-feruloyl-3-methoxytyramine-4'-O-β-D-glucopyranoside          | 23                   | 504[M–H] | 178,327,342 | C₁₅H₁₇NO₆ | [13]      |
| N-trans-feruloyl-3-methoxytyramine-4-O-β-D-glucopyranoside           | 23.51                | 504[M–H] | 178,327,342 | C₁₅H₁₇NO₆ | [13]      |
| 24-Hydroxycytasterone                                                | 24.31                | 581[M–H] | 373,391,499,535 | C₁₅H₁₇O₉ | [8,14]    |
| N-trans-Feruloyl tyramine                                           | 24.54                | 312[M–H] | 148,178,190,297 | C₁₅H₁₇NO₄ | [13,15]   |
| Kaempferol-3-O-glucoside                                            | 24.7                 | 447[M–H] | 153,267,285 | C₁₃H₁₉NO₂ | [16]      |
| N-trans-Feruloyl-3-methoxytyramine                                   | 24.96                | 575[M–H] | 283,311,395,413 | C₁₅H₁₇O₉ | [13,15]   |
| β-daucosterol                                                        | 25.12                | 342[M–H] | 148,178,190,297 | C₁₅H₁₇NO₆ | [17]      |
| N-trans-Feruloyl-3-methoxytyramine                                   | 26.5                 | 565[M+HCOO] | 199,301,319,501 | C₁₅H₁₇O₉ | [8,14]    |
| Cysterone                                                            | 27.15                | 565[M+HCOO] | 199,301,319,501 | C₁₅H₁₇O₉ | [8,14]    |
| Isocyasterone                                                        | 27.43                | 535[M–H] | 373,391,499 | C₁₅H₁₇O₉ | [8,14]    |
| Sengosterone                                                         | 27.58                | 312[M–H] | 148,178,297 | C₁₅H₁₇NO₄ | [13,15]   |
| N-cis-Feruloyltyramine                                               | 28.38                | 565[M+HCOO] | 199,301,319,501 | C₁₅H₁₇O₉ | [8,14]    |
| Precysterone                                                         | 29.4                 | 342[M–H] | 148,178,190,297 | C₁₅H₁₇NO₄ | [13,15]   |
| N-cis-Feruloyl-3-methoxytyramine                                     | 29.62                | 623[M–H] | 153,271,299,315 | C₁₅H₁₇NO₄ | [12]      |
| Isorhamnetin-3-O-rutinoside                                          | 30.22                | 539[M+HCOO] | 173,301,319,475 | C₁₅H₁₇O₉ | [8]       |
| Makisterone B                                                        | 35.02                | 553[M–H] | 301,319,489,507 | C₁₅H₁₇O₉ | [8,18,19] |
| Amarasterone A                                                       | 37.21                | 553[M+HCOO] | 301,319,471,507 | C₁₅H₁₇O₉ | [18]      |
| Amarasterone B                                                       | 45.83                | 837[M+HCOO] | 455,499,661,791 | C₁₅H₁₇O₉ | [20]      |
| Betavulgaroside II                                                   | 50.33                | 821[M–H] | 455,645,659,821 | C₁₅H₁₇O₉ | [21]      |
| Chukusetsusaponin IVa ethyl ester                                    | 50.74                | 809[M–H] | 471,647,809 | C₁₅H₁₇O₉ | [21]      |
| 28-O-β-D-glucuronopyranosyl-(1→4)-β-D-glucopyranosyl hederagenin     | 51.49                | 969[M–H] | 455,645,807 | C₁₅H₁₇O₉ | [21,23]   |
| Chukusetsusaponin V methyl ester                                    | 51.89                | 29[M–H]  | 455,613,793,955 | C₁₅H₁₇O₉ | [24]      |
| Achyranthisoside D                                                   | 52.74                | 955[M–H] | 455,631,793 | C₁₅H₁₇O₉ | [24]      |
| Ginsenoside Ro                                                       | 52.75                | 925[M–H] | 455,631,793 | C₁₅H₁₇O₉ | [24]      |
| Chukusetsusaponin IV                                                 | 52.81                | 1101[M–H] | 455,793,955 | C₁₅H₁₇O₉ | [24]      |
| 3-O-[β-D-glucuronopyranosyl-(1→2)-α-L-rhamnopyranosyl- (1→3)-β-D-    | 53.95                | 793[M–H] | 455,569,631 | C₁₅H₁₇O₉ | [22,24]   |
| glucuronopyranosyl] 3-O-[β-D-glucuronopyranosyl- (1→3)-β-D-           | 54.98                | 953[M–H] | 455,791,807,909 | C₁₅H₁₇O₉ | [22,24]   |
| glucuronopyranosyl] 3-O-[β-D-glucuronopyranosyl- (1→3)-β-D-           | 55.1                 | 793[M–H] | 455,631,731 | C₁₅H₁₇O₉ | [22,24]   |
| glucuronopyranosyl] 3-O-[β-D-glucuronopyranosyl- (1→3)-β-D-           | 55.54                | 807[M–H] | 455,685,645,745 | C₁₅H₁₇O₉ | [22,24]   |
| glucuronopyranosyl] 3-O-[β-D-glucuronopyranosyl- (1→3)-β-D-           | 55.74                | 807[M–H] | 455,685,645,745 | C₁₅H₁₇O₉ | [22,24]   |
| glucuronopyranosyl] 3-O-[β-D-glucuronopyranosyl- (1→3)-β-D-           | 56.49                | 955[M–H] | 455,631,793,853 | C₁₅H₁₇O₉ | [24]      |
| glucuronopyranosyl] 3-O-[β-D-glucuronopyranosyl- (1→3)-β-D-           | 57.75                | 939[M–H] | 455,613,731,793 | C₁₅H₁₇O₉ | [24]      |
| glucuronopyranosyl] 3-O-[β-D-glucuronopyranosyl- (1→3)-β-D-           | 58.74                | 793[M–H] | 455,613,673,793 | C₁₅H₁₇O₉ | [24]      |
| Betavulgaroside IV                                                   | 60.17                | 777[M–H] | 455,631,701 | C₁₅H₁₇O₉ | [22]      |
| Oleanolic acid 3-O-β-D-glucuronopyranoside                           | 60.39                | 631[M–H] | 455,613,631 | C₁₅H₁₇O₉ | [24]      |
normal conditions, while the elevated level of COX-2 could be caused by inflammation. TXA2 as a strong inducer of platelet aggregation and vasoconstriction obviously increases in blood stasis.\[32\] The release of COX-2 will increase the level of TXA2, which would ultimately promote platelet adhesion and aggregation and increase the risk of blood stasis.\[33\] The present study revealed that CO and ACO effectively reduced the levels of IL-6, NO, TNF-\(\alpha\), COX-2 and improved whole blood viscosity and plasma viscosity on acute blood stasis model rats. Therefore, our study demonstrated that CO and ACO have therapeutic effect on acute blood stasis model rats through improving blood rheology and reducing the levels of inflammatory cytokines.

In the current study, forty components were identified from ACO by HPLC-QTOF/MS/MS and most of them are phytoecdysteroids and saponins. As the main ingredient of ACO, Ginsenoside Ro was reported to have antioxidant activities through inhibiting the levels of MDA, ROS and promoting SOD activity.\[34\] What is more, Ginsenoside Ro and \(\beta\)-ecdysterone have been reported to possess anti-inflammatory activities via downregulating the expression of matrix metalloproteinase (MMP 3, MMP 9), COX-2 and inhibiting nuclear factor-kappaB p65 and IkappaB-\(\alpha\) phosphorylation in IL-1\(\beta\)-induced rat chondrocytes.\[35,36\] Chikusetsusaponin IVa presented significant antithrombotic effects in a stasis model of venous thrombosis and anticoagulation effects \textit{in vitro}.\[37\] Chikusetsusaponin IVa and chikusetsusaponin IVa methyl ester displayed suppressive effects on lipopolysaccharide-induced NO, prostaglandin E2, TNF-\(\alpha\), IL-6, and IL-1\(\beta\) production in RAW 264.7 cells and exhibited potential anti-inflammatory effect.\[38\] Chinese Pharmacopoeia takes the content of cyasterone as the quality standard of C. officinalis Kuan, and chikusetsusaponin IV is one of the main saponins in ACO. However, there is seldom report on their pharmacological activities.

SOD is one of the major defense mechanisms to protect cells against ROS damage.\[39\] MDA is commonly used as a biomarker of oxidative stress.\[40\] ET and NO play key roles in regulating cardiovascular system function and are involved in a variety of pathological procedures of cardiovascular disease.\[41\] The damage of HUVECs enhance the release of ET and causes vasoconstriction. eNOS is primarily responsible for the endothelium-dependent vasodilatation, and the activation of eNOS promotes the production of NO.\[42\] Thrombin-induced HUVECs damage experiment demonstrated that cyasterone and chikusetsusaponin IV have significant protective effects on HUVECs through inhibiting levels of TXA2, ET, MDA, COX-2 and promoting the activities of eNOS and SOD.

Aspirin, a positive drug, is widely used as an anti-inflammatory, antithrombotic, and even an anti-malignant agent. Even though it possesses great efficacy, its adverse effects should not be ignored, such as allergic reaction and adverse reactions of the blood system, digestive system, and nervous system. Compared to aspirin, C. officinalis Kuan has great advantages, such as reliable efficacy, lower side effects, and toxicity. Especially, the effects of cyasterone (100 \(\mu\)M) on inhibiting levels of COX-2, ET and promoting the activity of SOD were better than aspirin (100 \(\mu\)M). Hence, \textit{C. officinalis} Kuan as a clinically safe

---

**Figure 5:** Effects of cyasterone and chikusetsusaponin IV on the levels of malondialdehyde (a), superoxide dismutase (b), cyclooxygenase-2 (c), endothelial nitric oxide synthase (d), thromboxane 2 (e), and endothelin (f) with cyasterone, chikusetsusaponin IV (50, 100, and 200 \(\mu\)M) for 24 h, and then stimulated without or with thrombin (15 U/mL) for 24 h. Aspirin (100 \(\mu\)M) was taken as a positive control. Results are expressed as mean \pm standard deviation of six independent experiments. ###\(P < 0.001\) versus blank group; *\(P < 0.05\), **\(P < 0.01\), ***\(P < 0.001\) versus Model group. *\(P < 0.05\), **\(P < 0.01\), ***\(P < 0.001\) as compared with aspirin group.
and effective TCM may be considered as one of the useful drugs for the development of blood-activating agents.

CONCLUSION

The present study has demonstrated that CO and ACO showed significant improving blood rheology and anti-inflammatory effects on acute blood stasis model rats by improving whole blood viscosity, plasma viscosity and reducing the levels of IL-6, NO, TNF-α, and COX-2. HPLC-QTOF/MS/MS was used to identify components of ACO, mainly as phytoecdysteroids (e.g., 24-hydroxycyasterone and cyasterone) and saponins compounds (e.g., Ginsenoside Ro and chikusetsusaponin IV). Cysteine and chikusetsusaponin IV possessed significant protective effects on thrombin-induced HUVECs damage model by inhibiting levels of TXA2, ET, MDA, COX-2 and promoting the activities of eNOS and SOD. What's more, the inhibition of COX-2, ET and promotion of SOD in cysteine (100 μM) were better than aspirin group (100 μM). The data and the result of our investigation showed that CO and ACO possessed a significant therapeutic effect on acute blood stasis model rats through improving blood rheology and reducing inflammation and the representative components of cyasterone and chikusetsusaponin IV showed significant anti-inflammatory, antioxidant, and anticoagulant effects on thrombin-induced HUVECs damage model.

Acknowledgements

This study is supported by Natural Science Foundation of Jiangsu Province, China (No. BK20161575), Key Laboratory of Therapeutic Material of Chinese Medicine, Jiangsu Province, China Science and technology innovation risk fund project of Nanjing University of Chinese Medicine, China (CX2015050), and the Priority Academic Program Development of Jiangsu Higher Education Institutions, China.

Financial support and sponsorship

This study is supported by Natural Science Foundation of Jiangsu Province, China (No. BK20161575), Key Laboratory of Therapeutic Material of Chinese Medicine, Jiangsu Province, China science and technology innovation risk fund project of Nanjing University of Chinese Medicine, China (CX2015050), and the Priority Academic Program Development of Jiangsu Higher Education Institutions, China.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Beijing: China Medical Science Press; 2010. p. 35-6.
2. Bin XY, Shu GM, He GX, Ai L, Zhou XJ, Wu SH. Comparing study on anti-inflammatory effects of Cyathula officinalis Kuan and its adulterants. Resour Dev Mark 2013;4:341-2, 384.
3. Feng H, Du X, Tang J, Cao X, Han X, Chen Z, et al. Enhancement of the immune responses to foot-and-mouth disease vaccination in mice by oral administration of a novel polysaccharide from the roots of Radix Cyathulae officinalis Kuan (RC). Cell Immunol 2013;281:111-21.
4. Han X, Shen S, Liu T, Du X, Cao X, Feng H, et al. Characterization and antioxidant activities of the polysaccharides from Radix Cyathulae officinalis Kuan. Int J Biol Macromol 2015;72:544-52.
5. Chen XM, Tan GY. Structural elucidation and antitumor activity of a fructan from Cyathula officinalis Kuan. Carbohydr Res 2003;338:1235-41.
6. Yang YH, Yin L, Zhu XQ, Duan JA. Preparation of the saponins of Cyathula officinalis Kuan and its protection effect of endothelial cells (HUVEC) stimulated by sodium urate solution (MSU). Intl Tradit Chin Med 2010;2:15-8.
7. Wang Y, Yan J, Li S, Cai X, Wang W, Luo K, et al. Pharmacokinetics and tissue distribution study of tanshinone IIIA after oral administration of Buxhun Huoxue Qubi granules to rats with blood stasis syndrome. Pharmacobmag 2014;10:298-91.
8. Zhou R, Li BG, Zhang GL. Chemical study on Cyathula officinalis Kuan. J Asian Nat Prod Res 2006;7:245-52.
9. Qiao JQ, Xu D, Lian HZ, Ge X. Analysis of related substances in synthethical arbutin and its intermediates by HPLC-UV and LC-ESI-MS. Res Chem Intermediates 2015;41:691-703.
10. Jiang P, Ma Y, Gao Y, Li Z, Liu S, Xu Z, et al. Comprehensive evaluation of the metabolism of genipin-1,8-d-gentisicis in vitro and in vivo by using HPLC-Q-TOF. J Agric Food Chem 2016;64:5490-8.
11. Hochschuld JL. The chemical constituents and their antioxidant activity of the stem of Rhododendron mucronulatum, Nat Prod Sci 2005;11:97-102.
12. Li K, Gao C, Li W. Study on fragmentation of vittexin and isorhamnetin-3-O-beta-D-rutinoside using electrospray quadrupole time of flight mass spectrometry. Zhongguo Zhong Yao Za Zhi 2011;36:180-4.
13. Yang L, Jiang H, Wang QH, Yang BY, Kuang H, et al. A new furuloyl tyramine glycoside from the roots of Achyranthes bidentata. Chin J Nat Med 2012;10:16-9.
14. Fan QJ, Liu JL, Sun L, Zhang SL, Yuan JC, Tian ML, et al. Development of fingerprinting for quality evaluation of Cyathula officinalis Kuan by LC-DAD-ESI-TOF MS/MS coupled with multivariate statistical analysis. Anal Methods 2015;7:3395-401.
15. Sarker SD, Bartholomew B, Rash J. Alkaloids from Balanites aegyptiaca. Fitoterapia 2000;71:329-30.
16. Felipe DF, Bambilla LZ, Porto C, Pilau EJ, Cortez DA. Phytochemical analysis of Pfaffia glomerata infraredes by LC-ESI-MS/MS. Molecules 2014;19:51720-34.
17. Orban N, Kozák JO, Drávucz M, Kiss A. LC-MS method development to evaluate major triterpenes in citruses and cuticular waxes of grape berries. Int J Food Sci Technol 2009;44:869-73.
18. Takemoto T, Nomoto T, Hikino H. Structure of amaranteraster A and B novel C29 insect-moulting substances from Cyathula capitata. Tetrahedron Lett 1969;8:4953-6.
19. Budesinsky M, Vokác K, Hartmata J, Cvaška J. Additional minor ecdysteroid components of Leuzea carthamoides. Steroids 2008;73:502-14.
20. Kawahara Y, Hoshino T, Morimoto H, Shinizu T, Narukawa Y, Fuchino H, et al. LC-MS-based quantification method for Achyranthus root saponins. J Nat Med 2016;70:102-6.
21. Li J, Qi H, Qi LW, Yi L, Li P. Simultaneous determination of main phytoecdyesones and triterpenoids in radix Achyranthis bidentatae by high-performance liquid chromatography with diode array-evaporative light scattering detectors and mass spectrometry. Anal Chim Acta 2007;596:264-72.
22. Zhou R, Li BG, Zhang GL. Glycosides from roots of Cyathula officinalis Kuan. J Integr Plant Biol 2005;47:368-74.
23. Li JX, Hareyma T, Tezuka Y, Zhang Y, Miyahara T, Kadota S. Five new oleanolic acid glycosides from Achyranthes bidentata with inhibitory activity on osteoclast formation. Planta Med 2006;71:637-9.
24. Li JY, Wei HL, Qi LW, Chen J, Ren MT, Li P. Characterization and identification of saponins in Achyranthes bidentata by rapid-resolution liquid chromatography with electrospray ionization quadruple time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom 2010;24:2975-85.
25. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
26. Harisa GI. Blood viscosity as a sensitive indicator for pacitaxel induced oxidative stress in human whole blood. Saudi Pharm J 2015;23:48-54.
27. Trinity JD, BraxtenRAM, Richardson RS. Regulation of exercise blood flow: Role of free radicals. Free Radic Biol Med 2016;98:90-102.
28. Su S, Duan J, Cui W, Shang E, Liu P, Bai G, et al. Network-based biomarkers for cold coagulation blood stasis syndrome and the therapeutic effects of shaofu zhuju decoction in rats. Evid Based Complement Alternat Med 2013;2013:901943.
29. Kang VJ. Molecular and cellular mechanisms of cardio toxicity. Environ Health Perspect 2001;109 Suppl 1:27-34.
30. Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J 2015;170:1151-60.
31. Tuteja N, Chandra M, Tuteja R, Misra MK. Nicotin oxide as a unique bioactive signaling messenger in physiology and pathophysiology. J Biomed Biotechnol 2004;2004:227-27.
32. Zhao Y, Chu X, Pang XB, Wang SH, Du GH. Antithrombotic effects of the effective components of Leptospermum griffithianum in vivo and in vitro. Chin J Nat Med 2015;13:99-107.
33. Ungvari Z, Sarkadi-Nagy E, Bagi Z, Szollar L, Koller A. Simultaneously increased TxA2 activity in isolated arteries and platelets of rats with hypercoseminemia. Arterioscler Thromb Vasc Biol 2000;20:1203-8.
34. Jiang Z, Wang Y, Zhang X, Peng T, Li Y, Zhang Y. Protective effect of ginsenoside R0 on anoxic and oxidative damage in vitro. Biomol Ther (Seoul) 2012;20:544-9.
35. Zhang XH, Xu XX, Xu T. Ginsenoside R0 suppresses interleukin-1β-induced apoptosis and inflammation in rat chondrocytes by inhibiting NF-κB. Chin J Nat Med 2015;13:283-9.
36. Zhang X, Xu X, Xu T, Qin S. β-ecdysterone suppresses interleukin-1β-induced apoptosis and inflammation in rat chondrocytes via inhibition of NF-κB signaling pathway. Drug Dev Res 2014;75:195-201.
37. Dahmer T, Berger M, Barlette AG, Reck J Jr., Segalin J, Verza S, et al. Antithrombotic effect of chikusetsusaponin IVa isolated from Ilex paraguariensis (maté). J Med Food 2012;15:1073-80.
38. Lee HJ, Shin JS, Lee WS, Shim HY, Park JM, Jang DS, et al. Chikusetsusaponin IVa methyl ester isolated from the roots of Achyranthes japonica suppresses LPS-induced iNOS, TNF-α, IL-6, and IL-1β Expression by NF-κB and AP-1 Inactivation. Biol Pharm Bull 2016;39:657-64.
39. Gonzales R, Auclair C, Voisin E, Gautero H, Dhermy D, Boivin P. Superoxide dismutase, catalase, and glutathione peroxidase in red blood cells from patients with malignant diseases. Cancer Res 1984;44:4137-9.
40. Yao J, Cao X, Zhang R, Li YX, Xu ZL, Zhang DG, et al. Protective effect of baicalin against experimental colitis via suppression of oxidant stress and apoptosis. Pharmacogn Mag 2016;12:225-34.
41. Ryu JS, Shin CY, Yang SJ, Lee TS, La HO, Song HJ, et al. NMDA receptor and NO mediate ET-1-induced behavioral and cardiovascular effects in periaqueductal gray matter of rats. Arch Pharm Res 2001;24:64-8.
42. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: Ten years after, and continuing. Circ Res 2003;93:388-98.